Dr. Michael Davies, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Texas Health San Antonio School Of Dentistry

  Medical School, 2001

• Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases, 2012-05-17

• The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy, 2023-09-13

• Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts, 2021-02-19

• Clinical actionability enhanced through deep targeted sequencing of solid tumors, 2015-01-27

• Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma, 2023-03-09

• Profiles of Brain Metastases: Prioritization of Therapeutic Targets, 2018-10-09

• Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome, 2018-05-30

• Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma, 2020-04-15

• Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations, 2018-06-13

• Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma, 2021-03-11

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Utility of BRAF V600E immunohistochemistry expression pattern as a surrogate ofBRAFmutation status in 154 patients with advanced melanoma, 2015-05-06

• Somatic mutations in MAP3K5 attenuate its pro-apoptotic function in melanoma through increased binding to Thioredoxin, 2013-09-05

• Response and resistance to paradox breaking BRAF inhibitor in melanomasin vivoandex vivo, 2017-11-13

• Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities, 2019-02-19

• Genetic and genomic characterization of 462 melanoma patient-derived xenografts, tumor biopsies and cell lines, 2017-11-14

• ONCOGENIC BRAF(V600E) PROMOTES STROMAL CELL-MEDIATED IMMUNOSUPPRESSION VIA INDUCTION OF INTERLEUKIN-1 IN MELANOMA, 2012-07-31

• Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment, 2021-08-24

• Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PETIn Vivo, 2019-11-21

• Moving treatments earlier to move further forward, 2017-11-28

• Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy, 2022-06-15

• Phase I/II study of hepatic arterial infusion of nab-paclitaxel in patients with metastatic melanoma to the liver, 2018-02-05

• Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T cell Therapy, 2018-04-05

• A Landscape of Driver Mutations in Melanoma, 2012-07-20

• Co-targeting HGF-cMET signaling with MEK inhibitors in metastatic uveal melanoma, 2017-01-30

• Characterization of Human Cancer Cell Lines by Reverse-Phase Protein Arrays, 2017-02-13

• Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts, 2021-01-07

• Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases, 2021-01-06

• Microenvironmental landscape of human melanoma brain metastases in response to immune checkpoint inhibition, 2022-08-03

• Exome sequencing identifies GRIN2A as frequently mutated in melanoma, 2011-04-15

• Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities, 2022-09-01

• Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set, 2016-10-25

• Role of ElevatedPHIPCopy Number as a Prognostic and Progression Marker for Cutaneous Melanoma, 2018-05-18

• Loss of PTEN promotes resistance to T cell-mediated immunotherapy, 2015-12-08

• Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases, 2023-02-01

• Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment, 2022-01-07

• Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis, 2018-10-11

• B cells and tertiary lymphoid structures promote immunotherapy response, 2020-01-15

• MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma, 2015-11-20

• ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma, 2018-08-16

• Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes, 2021-10-22

• Dabrafenib plus trametinib in patients withBRAFV600-mutant melanoma brain metastases (COMBI-MB): a multi-cohort, open-label, phase 2 trial, 2017-06-04

• Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy), 2019-07-22

• The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy, 2018-02-12

• Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma, 2013-10-01

• Clinicopathological features and clinical outcomes associated withTP53andBRAFNon-V600mutations in cutaneous melanoma patients, 2016-12-02

• Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth, 2023-06-30

• Exon capture analysis of G protein-coupled receptors identifies activating mutations inGRM3in melanoma, 2011-09-25

• Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor, 2014-07-17

• Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma, 2014-08-22

• Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance, 2017-03-01

• Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-a in patients with metastatic melanoma, 2014-12-20

• AKT1 activation promotes the development of melanoma metastases, 2015-10-22

• Anin vivoreporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma, 2016-08-03

• Nodal recurrence is a primary driver of early relapse for patients with sentinel lymph node positive melanoma in the modern therapeutic era, 2021-04-15

• ErbB3/ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas, 2015-07-23

• Assessment of Compliance with Texas Legislation Banning Indoor UV Tanning by Minors, 2017-02-01

• Large-scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines, 2020-11-05

• The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF, 2014-07-23

• Tumor-associated B-cells induce tumor heterogeneity and therapy resistance, 2017-09-19

• Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target, 2014-05-06

• Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients, 2012-10-02

• The multi-faceted roles of the PI3K-AKT pathway in melanoma, 2015-01-15

• Melanoma central nervous system metastases: current approaches, challenges, and opportunities, 2016-10-22

• Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis, 2019-04-17

• Targeted therapy strategies for melanoma brain metastasis, 2021-11-27

• Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression, 2017-04-25

• Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases, 2019-02-20

• Pathways and therapeutic targets in melanoma, 2014-04-08

• Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy, 2022-04-12

• Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy, 2017-02-21

• Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma, 2022-05-02

• Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis, 2021-01-04

• Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition, 2020-06-22

• Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results, 2023-03-30

• Gas6/Axl is the sensor of Arginine-Auxotrophic Response in Targeted Chemotherapy with Arginine-Depleting Agents, 2015-06-22

• iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation, 2021-02-12

• Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600mutations, 2014-08-27

• A pre-existing rare PIK3CAE545Ksubpopulation confers clinical resistance to MEK plus CDK4/6 inhibition inNRASmelanoma and is dependent on S6K1 signaling, 2018-03-01

• Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis R. I. Ramoset al., 2020-06-05

• Multi-modal molecular programs regulate melanoma cell state, 2022-07-09

• Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy), 2018-07-21

• Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents, 2012-12-18

• RAC1 P29S regulates PD-L1 expression in melanoma, 2015-11-28

• BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Anti-tumor Activity of Adoptive Immunotherapy in Mice, 2012-11-30

• Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma, 2015-07-13

• Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker, 2020-10-05

• Inducible nitric oxide synthase (iNOS) drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2, 2014-01-07

• Converting biology into clinical benefit: lessons learned from BRAF inhibitors, 2015-09-05

• FOXD3 Regulates VISTA Expression in Melanoma, 2020-01-14

• Obesity is associated with altered tumor metabolism in metastatic melanoma, 2023-01-04

• Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype, 2020-09-11

• In vivoERK1 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma, 2019-07-03

• Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma, 2020-10-20

• ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties, 2018-07-12

• A comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma, 2017-11-14

• In vivoE2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms, 2018-03-01

• A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors, 2017-10-19

• Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma, 2022-10-17

• Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma, 2012-01-05

• mTORC1 activation blocksBrafV600E-induced growth-arrest, but is insufficient for melanoma formation, 2015-01-12

• Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma, 2016-09-16

• Resistance mechanisms to genetic suppression of mutantNRASin melanoma, 2017-09-13

• Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+T cells and synergizes with PI3Kß inhibition in PTEN loss melanoma, 2019-08-01

• Melanoma brain metastases: current areas of investigation and future directions, 2016-11-08

• Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid, 2010-06-09

• Neoadjuvant relatlimab and nivolumab in resectable melanoma, 2022-10-26

• ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma, 2017-09-08

• Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature, 2019-11-21

• Metabolic Strategies of Melanoma Cells: Mechanisms, Interactions with the Tumor Microenvironment, and Therapeutic Implications, 2017-11-02

• Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma, 2016-01-18

• The State of Melanoma: Challenges and Opportunities, 2016-04-17

• Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma, 2020-01-14

• Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade, 2016-06-14

• Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade, 2023-07-18

• Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas, 2018-06-14

• Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-?B Pathway in Melanoma, 2017-04-07

• Future perspectives in melanoma research Meeting report from the "Melanoma Bridge”. Napoli, December 1st-4th 2015, 2016-11-15

• AKT1E17Kactivates focal adhesion kinase and promotes melanoma brain metastasis, 2019-05-28

• Melanoma and immunotherapy bridge 2015 Naples, Italy. 1-5 December 2015, 2016-07-25

• New Strategies in Melanoma: Molecular Testing in Advanced Disease, 2012-01-24

• Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs, 2018-07-19

• Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response, 2021-12-23

• Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene, 2017-11-16

• BRAF, NRAS,ANDKITSEQUENCING ANALYSIS OF SPINDLE CELL MELANOMA, 2012-07-19

• Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma, 2017-04-07

• A highly recurrent RPS27 5'UTR mutation in melanoma, 2014-06-01

• Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma, 2017-04-28

• Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression, 2016-01-20

• Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanomain vivoand synergizes with chemotherapy, 2010-03-09